Protalix BioTherapeutics voluntarily delists from Tel Aviv Stock Exchange; NYSE American listing unaffected

Protalix BioTherapeutics, Inc.

Company requested immediate delisting of common stock from TASE; effective three months from request.
Stock continues trading on TASE during the three-month period; all shares expected to transfer to NYSE American.
NYSE American listing and SEC reporting obligations remain unchanged; company will focus on U.S. capital market.
Decision aims to reduce operating costs by having a single set of listing rules and regulations.
No financial impact disclosed; delisting is voluntary and procedural.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.